Dimerix and FUSO sign agreement to commercialize DMX-200 in Japan.
Posted on: 06/01/2025
Dimerix receives IDMC approval to continue ACTION3 kidney trial unchanged.
Posted on: 19/11/2024
Dimerix enhances cash position with a $7.9 million R&D tax rebate.
Posted on: 14/11/2024
Dimerix reports significant progress in DMX-200 licensing and clinical trials.
Posted on: 23/07/2024